Phase III study: Ocrelizumab significantly reduces disease activity in PPMS patients

Accessed on 1 Mar 2016 from http://www.news-medical.net/news/20160227/Phase-III-study-Ocrelizumab-significantly-reduces-disease-activity-in-PPMS-patients.aspx.